AbbVie, Genmab's Epkinly sets 'new standard of care' in first-line lymphoma in Phase 3

AbbVie and Genmab's bispecific antibody Epkinly demonstrated a 51% improvement in progression-free survival in first-line diffuse large B cell lymphoma during Phase 3 trials, potentially establishing a new standard of care and setting up competition with Roche's Polivy.

This Wire brief sits within Fusion42's coverage of Biotech.